Skip to main content

Table 1 MPN Patients’ Demographics by Smoking Status

From: Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care

Demographics Current/Former (N = 181) Never (N = 254) Total (N = 435) p-value
Age (Mean, Range) 61.5 (38.0–86.0) 60.1 (26.0–84.0) 60.7 (26.0–86.0) 0.1879
Gender (n, %)     0.0578
 Male 55 (30.4%) 56 (22.0%) 111 (25.5%)  
 Female 126 (69.6%) 198 (78.0%) 324 (74.5%)  
Country of Residence (n, %)     0.1333
 US 115 (63.5%) 175 (68.9%) 290 (66.7%)  
 Canada 10 (5.5%) 17 (6.7%) 27 (6.2%)  
 Australia 30 (16.6%) 21 (8.3%) 51 (11.7%)  
 United Kingdom 10 (5.5%) 17 (6.7%) 27 (6.2%)  
 Other 16 (8.8%) 24 (9.4%) 40 (9.2%)  
Language (n, %)     0.3864
 English 166 (91.7%) 239 (94.1%) 405 (93.1%)  
 Spanish 3 (1.7%) 1 (0.4%) 4 (0.9%)  
 Other 12 (6.6%) 14 (5.5%) 26 (6.0%)  
MPN subtype (n, %)     0.0623
 ET 44 (24.3%) 75 (29.5%) 119 (27.4%)  
 PV 75 (41.4%) 118 (46.5%) 193 (44.4%)  
 MF 62 (34.3%) 61 (24.0%) 123 (28.3%)  
MF type (n, %)a     0.2383
 Primary myelofibrosis 34 (54.8%) 24 (39.3%) 58 (47.2%)  
 Post-ET myelofibrosis 18 (29.0%) 23 (37.7%) 41 (33.3%)  
 Post-PV myelofibrosis 10 (16.1%) 14 (23.0%) 24 (19.5%)  
MPN duration (n, %)     0.8305
  < ½ Year 6 (3.3%) 13 (5.2%) 19 (4.4%)  
 ½ - 3 Years 55 (30.4%) 72 (28.6%) 127 (29.3%)  
 3–10 Years 65 (35.9%) 92 (36.5%) 157 (36.3%)  
  > 10 Years 55 (30.4%) 75 (29.8%) 130 (30.0%)  
Prior bone marrow transplantation (n, %) 6 (3.3%) 0 (0.0%) 6 (1.4%) 0.0049
Splenomegaly (n, %) 56 (40.3%) 71 (34.3%) 127 (36.7%) 0.4798
Prior splenectomy 6 (3.3%) 2 (0.8%) 8 (1.9%) 0.0725
Prior thrombosis (n, %)     0.5062
 Blood Clot in Deep Veins of the Leg or Arm 13 (7.3%) 24 (9.6%) 37 (8.7%)  
 Blood Clot in Veins of the Head 1 (0.6%) 7 (2.8%) 8 (1.9%)  
 Blood Clot in Veins of the Abdomen 7 (3.9%) 13 (5.2%) 20 (4.7%)  
 Stroke or Transient Ischemic Attack 15 (8.4%) 21 (8.4%) 36 (8.4%)  
 Heart Attack 5 (2.8%) 5 (2.0%) 10 (2.3%)  
Prior hemorrhage (n, %) 25 (13.8%) 31 (12.3%) 56 (12.9%) 0.3913
Current treatment of MPN (n, %)
 Aspirin 118 (65.2%) 200 (78.7%) 318 (73.1%) 0.0021
 Hydroxyurea 56 (30.9%) 88 (34.6%) 144 (33.1%) 0.4696
 Interferon 8 (4.4%) 11 (4.3%) 19 (4.4%) 1.0000
 Ruxolitinib 41 (22.7%) 54 (21.3%) 95 (21.8%) 0.7258
 Anagrelide 9 (5.0%) 6 (2.4%) 15 (3.4%) 0.1833
 Phlebotomy requirement 34 (18.8%) 64 (25.2%) 98 (22.5%) 0.1305
 RBC transfusion requirement 15 (8.3%) 6 (2.4%) 21 (4.8%) 0.0058
Comorbidity (n, %)
 Anemia 101 (56.1%) 101 (40.1%) 202 (46.8%) 0.0004
 Heart disease 23 (12.7%) 25 (9.8%) 48 (11.0%) 0.5488
 Chronic obstructive pulmonary disorder 11 (6.1%) (1 (0.4%) 12 (2.8%) 0.0004
 Current opioid use for pain management 41 (23.6%) 27 (11.2%) 68 (16.4%) 0.0011
  1. MPN Philadelphia-negative chronic myeloproliferative neoplasms, RBC Red blood cell
  2. aThe number of MF patients is used as the denominator: Current/Former Smokers (N = 61), Never Smokers (N = 62), Total (N = 123)